Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma

Table 2

Univariate analysis of clinical factors for PFS and OS in 182 patients.

Characteristics	OS			PFS
	HR	95%CI	P value	HR	95%CI	P value
Age (>60)	0.862	0.497-1.496	0.597	0.840	0.489-1.443	0.528
Gender	0.923	0.531-1.602	0.775	0.918	0.534-1.576	0.755
B symptoms	0.504	0.279-0.911	0.023	0.500	0.278-0.900	0.021
ECOG PS (⩾2)	0.427	0.231-0.788	0.007	0.497	0.271-0.912	0.024
LDH (>ULN)	0.405	0.232-0.707	0.001	0.385	0.222-0.667	0.001
Stage (III and IV)	0.527	0.301-0.921	0.025	0.574	0.331-0.993	0.047
Bone marrow involvement	2.227	0.945-5.252	0.067	0.506	0.215-1.191	0.119
IPI (>2)	0.379	0.216-0.665	0.001	0.420	0.241-0.732	0.002
Extranodal sites of disease (>1)	0.451	0.247-0.824	0.010	0.507	0.280-0.919	0.025
Pathology type	0.895	0.447-1.789	0.753	0.830	0.416-1.656	0.598
NLR⩾150	1.909	1.066-3.418	0.030	0.527	0.298-0.932	0.028
PLR⩾2.32	0.551	0.314-0.969	0.038	0.528	0.302-0.924	0.025

Abbreviations: NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio.